Kurma Partners closed a €215 million fund, its fourth and largest, aimed at backing disruptive therapeutic solutions. The venture firm said the vehicle will support a mix of platform and development-stage investments, building on prior exits including acquisitions tied to Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. The larger fund size suggests confidence that European venture capital is ready to place bigger bets on therapeutics with differentiated mechanisms and defensible development paths. For founders, the update provides another signal that capital remains available—especially for categories where clinical execution can be accelerated by platform IP and strong translational teams.